Acceleron Pharma (XLRN) Reports In-Line Q4 EPS

Acceleron Pharma (NASDAQ: XLRN) reported Q4 EPS of ($0.62), in-line with the analyst estimate of ($0.62). Revenue for the quarter came in at $3.7 million versus the consensus estimate of $3.66 million.

For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c